Thermo Fisher Scientific Inc. (TMO) Analysts See $3.19 EPS

Thermo Fisher Scientific Inc. (NYSE:TMO) Logo
Investors sentiment decreased to 0.85 in Q3 2018. Its down 0.23, from 1.08 in 2018Q2. It dived, as 41 investors sold Thermo Fisher Scientific Inc. shares while 434 reduced holdings. 111 funds opened positions while 295 raised stakes. 333.46 million shares or 0.38% more from 332.19 million shares in 2018Q2 were reported.
Moreover, Ruggie Group has 0% invested in Thermo Fisher Scientific Inc. (NYSE:TMO) for 29 shares. 51,048 are held by Amalgamated Bancshares. Sol Capital Mngmt Company, a Maryland-based fund reported 2,346 shares. Wilbanks Smith & Thomas Asset Management Limited Company holds 0.03% of its portfolio in Thermo Fisher Scientific Inc. (NYSE:TMO) for 2,292 shares. 2,123 were accumulated by Jefferies Group Ltd Liability. Moreover, Kentucky Retirement Fund has 0.41% invested in Thermo Fisher Scientific Inc. (NYSE:TMO). Icm Asset Mgmt Inc Wa reported 0.3% of its portfolio in Thermo Fisher Scientific Inc. (NYSE:TMO). Hayek Kallen Mngmt holds 23,499 shares. Court Place Advsrs has 2,209 shares for 0.2% of their portfolio. Caisse De Depot Et Placement Du Quebec reported 753,082 shares. Citadel Advsrs Lc accumulated 3,401 shares. The Ohio-based Mai Management has invested 0.03% in Thermo Fisher Scientific Inc. (NYSE:TMO). Comerica Secs Incorporated stated it has 0.16% of its portfolio in Thermo Fisher Scientific Inc. (NYSE:TMO). Fca Tx owns 2,000 shares. Levin Strategies Limited Partnership invested in 0.21% or 49,416 shares.

Since October 1, 2018, it had 0 buys, and 5 sales for $39.04 million activity. Jacks Tyler sold $277,176 worth of stock. CASPER MARC N sold $31.07 million worth of stock or 125,520 shares. Herrema Gregory J. sold 17,235 shares worth $4.26M.

Analysts expect Thermo Fisher Scientific Inc. (NYSE:TMO) to report $3.19 EPS on January, 30 before the open.They anticipate $0.40 EPS change or 14.34 % from last quarter’s $2.79 EPS. TMO’s profit would be $1.28 billion giving it 18.59 P/E if the $3.19 EPS is correct. After having $2.62 EPS previously, Thermo Fisher Scientific Inc.’s analysts see 21.76 % EPS growth. The stock decreased 1.19% or $2.85 during the last trading session, reaching $237.15. About 380,304 shares traded. Thermo Fisher Scientific Inc. (NYSE:TMO) has risen 27.72% since January 14, 2018 and is uptrending. It has outperformed by 27.72% the S&P500.

Thermo Fisher Scientific Inc. (NYSE:TMO) Ratings Coverage

Among 7 analysts covering Thermo Fisher Scientific (NYSE:TMO), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Thermo Fisher Scientific had 10 analyst reports since July 26, 2018 according to SRatingsIntel. The firm earned “Neutral” rating on Monday, September 17 by Goldman Sachs. Morgan Stanley maintained Thermo Fisher Scientific Inc. (NYSE:TMO) rating on Thursday, July 26. Morgan Stanley has “Overweight” rating and $242 target. The stock of Thermo Fisher Scientific Inc. (NYSE:TMO) has “Overweight” rating given on Thursday, January 3 by Barclays Capital. The rating was maintained by Morgan Stanley on Wednesday, October 10 with “Overweight”. The stock of Thermo Fisher Scientific Inc. (NYSE:TMO) has “Buy” rating given on Wednesday, October 10 by Citigroup. As per Monday, September 24, the company rating was maintained by Barclays Capital. The firm has “Outperform” rating given on Thursday, October 25 by Robert W. Baird. As per Thursday, October 18, the company rating was downgraded by Cleveland. The stock of Thermo Fisher Scientific Inc. (NYSE:TMO) has “Overweight” rating given on Thursday, October 25 by Morgan Stanley.

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide. The company has market cap of $95.47 billion. The Company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of new drugs and vaccines, as well as diagnosis of diseases to pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets. It has a 37.42 P/E ratio. The Company’s Analytical Instruments segment offers instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories.

More important recent Thermo Fisher Scientific Inc. (NYSE:TMO) news were published by: Seekingalpha.com which released: “Thermo Fisher Scientific beats by $0.07, beats on revenue – Seeking Alpha” on October 24, 2018, also Benzinga.com published article titled: “Thermo Fisher Scientific Inc (NYSE:TMO) – Q3 Earnings Preview: Thermo Fisher Scientific – Benzinga”, Seekingalpha.com published: “Thermo Fisher in-licenses CRISPR technologies – Seeking Alpha” on September 18, 2018. More interesting news about Thermo Fisher Scientific Inc. (NYSE:TMO) was released by: Seekingalpha.com and their article: “Thermo Fisher Scientific declares $0.17 dividend – Seeking Alpha” with publication date: November 08, 2018.

Thermo Fisher Scientific Inc. (NYSE:TMO) Institutional Positions Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.